17,261 trials
Hepatitis C, Chronic
Primary: SVR12: Plasma HCV RNA Level Less Than 25 IU/mL at 12 Weeks After End of Treatment (EOT) — 61.1; 52.9 Percentage of participants
Head and Neck Cancer
Primary: To Determine the Overall Response Rate (CR+PR) — 8 participants
Head and Neck · Squamous Cell Cancer
Primary: Number of Patients With Overall Objective Response — 4; 2; 12; 5 participants
Lung Neoplasms · Carcinoma, Non-Small-Cell Lung
Primary: Number of Participants With Treatment Emergent Adverse Events (TEAEs), Serious TEAEs, TEAEs Leading to Death, and TEAEs With Cancer and Leukemia Group B (CALGB) Toxicity…
Critical Limb Ischemia
Primary: Number of Participants With Adverse Events as a Measure of Safety and Major Limb Amputation Free Survival Post BMMNC Administration — 14; 3; 2; 2 participants
Small Cell Lung Cancer
Primary: Time to Disease Progression - Median Time to Progression and Log-Rank Test — 5.68; 5.62 Months — p=0.10
Locally Advanced (Unresectable) or Metastatic Adenocarcinoma of the Gastric and Gastro-esophageal Junction
Primary: Immune-related Progression Free Survival (irPFS) as Per Assessment of a Blinded Independent Review Committee (IRC) According to Immune Related Response Criteria (irRC)…
Cervical Adenocarcinoma · Cervical Adenosquamous Carcinoma · Cervical Squamous Cell Carcinoma
Primary: Overall Objective Response Rate (CR+PR) — 2; 5; 8 participants
Diabetes · Diabetes Mellitus, Type 2
Primary: Change in Glycosylated Haemoglobin (HbA1c) — -1.31; -1.46; -1.29 percentage of glycosylated haemoglobin
Diabetes · Diabetes Mellitus, Type 2
Primary: Change in Glycosylated Haemoglobin (HbA1c) — -1.26; -1.28; -1.46; -1.49 percentage of glycosylated haemoglobin
Overweight
Primary: Weight Change (in kg.) After Each Intervention — -0.39; 0.02 kg weight change
Diabetes · Diabetes Mellitus, Type 1
Primary: Rate of Major and Minor Hypoglycaemic Episodes — 0; 0; 62.97; 80.84 Episodes /year of patient exposure
Diabetes · Diabetes Mellitus, Type 1
Primary: Change in Glycosylated Haemoglobin (HbA1c) — -0.54; -0.57; -0.62 percentage of glycosylated haemoglobin
Hepatitis C, Chronic
Primary: Virological Response 4 Weeks After the End of Treatment With BI 201335 or Placebo — 0.0; 14.3; 59.7; 75.0 percentage of patients
Non-Squamous Non-Small Cell Lung Cancer
Primary: Progression-free Survival (Tumour Assessments According to RECIST Criteria) — 223 Days